Qiagen N.V. (QGEN)
After hours:
| Previous Close | 49.31 |
| Open | 48.79 |
| Bid | 0.00 x 800 |
| Ask | 49.85 x 900 |
| Day's Range | 48.72 - 49.85 |
| 52 Week Range | 40.38 - 51.30 |
| Volume | |
| Avg. Volume | 701,496 |
| Market Cap | 11.339B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 24.90 |
| EPS (TTM) | 2.00 |
| Earnings Date | Feb 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.80 |
- Zacks
Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
Strong core growth offsets dwindling COVID-19 demand for Qiagen
Medical diagnostics company Qiagen offset a sharp fall in demand for COVID-19 products at the end of the year with a strong performance in its core businesses, the company said, announcing its full-year and fourth quarter results on Tuesday. Fourth quarter revenues came in at $498 million, a 14% fall compared with the same period last year. Revenues from COVID products fell 64% to $66 million, but this was offset by strong growth in non-COVID products, where revenues rose 8% to $432 million.
- Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
VENLO, Netherlands, February 07, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2022.
